¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primary carbon dioxide excess"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • carbon monoxide intoxication
    ÀÏ»êȭź¼ÒÁßµ¶
  • carbon monoxide poisoning
    ÀÏ»êȭź¼ÒÁßµ¶
  • carbon oxysulfide
    »ê¼ÒȲȭº»
  • carbon tetrachloride
    »ç¿°È­Åº¼Ò
  • carbon tetrachloride poisoning
    »ç¿°È­Åº¼ÒÁßµ¶
  • equivalent carbon
    ´ç·®Åº¼Ò
  • delayed primary suture
    Áö¿¬ÀÏÂ÷ºÀÇÕ
  • primary
    ÀÏÂ÷-, ¿ø¹ß-
  • primary action
    ÀÏÂ÷ÀÛ¿ë
  • primary affect hunger
    ÀÏÂ÷Á¤µ¿°¥¸Á, ÀÏÂ÷¾ÖÁ¤°¥¸Á
  • primary aldosteronism
    ¿ø¹ß¾Ëµµ½ºÅ×·ÐÁõ
  • primary amebic meningoencephalitis
    ¿ø¹ß¾Æ¸Þ¹Ù¼ö¸·³ú¿°
  • primary amenorrhea
    ¿ø¹ß¹«¿ù°æ
  • primary amnion
    ÀÏÂ÷¾ç¸·, ¿ø½Ã¾ç¸·
  • primary amyloidosis
    ¿ø¹ß¾Æ¹Ð·ÎÀ̵åÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • carbon arc lamp
    ź¼Ò¾ÆÅ©µî
  • carbon monoxide intoxication
    ÀÏ»êȭź¼ÒÁßµ¶
  • carbon monoxide poisoning
    ÀÏ»êȭź¼ÒÁßµ¶
  • carbon monoxide hemoglobin test
    ÀÏ»êȭź¼ÒÇì¸ð±Û·Îºó°Ë»ç
  • equivalent carbon
    ´ç·®Åº¼Ò
  • residual carbon
    ÀÜ¿©Åº¼Ò
  • total organic carbon
    ÃÑÀ¯±âź¼Ò
  • primary action
    ÀÏÂ÷ÀÛ¿ë, ÀÏÂ÷±â´É
  • primary amenorrhea
    ¿ø¹ß¹«¿ù°æ, ÀÏÂ÷¹«¿ù°æ
  • primary amnion
    ¿ø½Ã¾ç¸·, ÀÏÂ÷¾ç¸·
  • primary amyloidosis
    ¿ø¹ß¾Æ¹Ð·ÎÀ̵åÁõ
  • primary aqueous
    ¿ø¹æ¼ö, ÀÏÂ÷¹æ¼ö
  • primary olfactory receiving area
    ÀÏÂ÷Èİ¢¿µ¿ª
  • primary sensory area
    ÀÏÂ÷°¨°¢±¸¿ª
  • primary bronchus
    ÀÏÂ÷±â°üÁö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • primary aldosteronism
    ¿ø¹ß(¼º) ¾Ëµµ½ºÅ×·ÐÁõ(ê«Û¡àõ¡­ñø).
  • primary aldosteronism
    ¿ø¹ß(¼º) ¾Ëµµ½ºÅ×·ÐÁõ(ê«Û¡(àõ)¡­ñø)
  • primary amenorrhea
    ¿ø¹ß¼º ¹«¿ù°æ(ê«Û¡àõÙíêÅÌè), 1Â÷¼º ¹«¿ù°æ
  • primary amenorrhea
    ¿ø¹ß(¼º) ¹«¿ù°æ(ê«Û¡(àõ) ÙíêÅÌè)
  • primary amine
    ÀÏÂ÷¾Æ¹Î.
  • primary amnion
    ÀÏÂ÷¾ç¸·
  • primary amnion
    ¿ø½Ã¾ç¸·
  • primary amyloidosis
    ¿ø¹ß(¼º) ¾Æ¹Ð·Î À̵åÁõ.
  • primary amyloidosis
    ¿ø¹ß(¼º)(ê«Û¡(àõ)) ¾Æ¹Ð·Î À̵åÁõ
  • primary angle-closure glaucoma
    ¿ø¹ßÆó¼â°¢³ì³»Àå
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • primary aqueous
    ¿ø¹æ¼ö, ÀÏÂ÷¹æ¼ö
  • primary battery
    ÀÏÂ÷ÀüÁö(ìéó­ï³ò®).
  • primary battery
    ÀÏÂ÷ÀüÁö(ìéó­ï³ò®)
  • primary biliary cirrhosis
    ¿ø¹ß¼º ´ãÁó¼º °£°æº¯(Áõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • nitrogen dioxide
    ÀÌ»êÈ­Áú¼Ò(ì£ß«ûùòòáÈ).
  • nitrogen dioxide
    ÀÌ»êÈ­Áú¼Ò(ì£ß«ûùòòáÈ)
  • sulfur dioxide
    ÀÌ»êÈ­À¯È²(ì£ß«ûù×¼üÜ)
  • sulfur dioxide control
    ÀÌ»êȭȲ°¡½º±ÔÁ¦(Ëö Ë×Ì´Ì·ÊÙ˻̡).
  • sulfur dioxide poisoning
    ÀÌ»êȭȲ°¡½ºÁßµ¶(ÊÙÌ¡ËÄ).
  • thorium dioxide
    ÀÌ»êÈ­Åä·ý.
  • accommodative excess
    Á¶Àý°ú´Ù
  • antibody excess
    Ç×ü°úÀ×(ù÷ô÷Φí¥).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Primary amnion
    ÀÏÂ÷¾ç¸·
    [¿¾ ¿ë¾î] ÀÏÂ÷¾ç¸·
  • Primary villus
    ÀÏÂ÷À¶¸ð
    [¿¾ ¿ë¾î] ÀÏÂ÷À¶¸ð
  • Primary pregnancy
    ÀÏÂ÷ÀÓ½Å
    [¿¾ ¿ë¾î] ÀÏÂ÷ÀÓ½Å
  • Primary spermatocyte
    ÀÏÂ÷Á¤¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ÀÏÂ÷Á¤¸ð¼¼Æ÷
  • Primary spermatocyte
    ÀÏÂ÷Á¤¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] Á¦ÀÏÁ¤¸ð¼¼Æ÷
  • Primary nasal septum
    ÀÏÂ÷ÄÚÁß°Ý
    [¿¾ ¿ë¾î] ÀÏÂ÷ºñÁß°Ý
  • Primary hair follicle
    ÀÏÂ÷ÅÐÁÖ¸Ó´Ï
    [¿¾ ¿ë¾î] ÀÏÂ÷¸ð³¶
  • Primary sponge bone
    ÀÏÂ÷ÇØ¸é»À
    [¿¾ ¿ë¾î] ÀÏÂ÷ÇØ¸é°ñ
  • Primary pulmonary lobule
    ÀÏÂ÷ÇãÆÄ¼Ò¿±
    [¿¾ ¿ë¾î] ÀÏÂ÷Æó¼Ò¿±
  • Primary septum
    ù°»çÀ̸·
    [¿¾ ¿ë¾î] Á¦ÀÏÁß°Ý
  • Primary fissure
    ù°ƴ»õ
    [¿¾ ¿ë¾î] Á¦1·Ä
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • primary lysosome
    ÀÏÂ÷(ìéó­) ¶óÀ̼ÒÁ»
  • primary messenger
    ÀÏÂ÷ Àü·É(ìéó­îîÖµ)
  • primary metabolite
    ÀÏÂ÷ ´ë»ç¹°Áú(ìéó­ÓÛÞóÚªòõ)
  • primary oxaluria
    ¿ø¹ß¼º(ê«Û¡àõ) ¿Á»ì»ê´¢Áõ(Òãñø)
  • primary pigment
    ÀÏÂ÷ »ö¼Ò(ìéó­ßäáÈ)
  • primary plot
    ÀÏÂ÷(ìéó­) Ç÷Ô
  • primary prostaglandin
    ÀÏÂ÷(ìéó­) ÇÁ·Î½ºÅ¸±Û¶õµò
  • primary protein derivative
    ÀÏÂ÷ ´Ü¹éÁúÀ¯µµÃ¼
  • primary response
    ÀÏÂ÷ ´ëÀÀ(ìéó­Óßëë)
  • primary solvent
    ÀÏÂ÷ ¿ë¸Å(ìéó­éÁØÚ)
  • primary standard
    ÀÏÂ÷ Ç¥ÁØ(ìéó­øöñÞ)
  • primary stimulus
    ÀÏÂ÷ ÀÚ±Ø(ìéó­í©Ð½)
  • primary structure
    ÀÏÂ÷±¸Á¶(ìéó­Ï°ðã)
  • primary tissue culture
    ÀÏÂ÷ Á¶Á÷¹è¾ç(ìéó­ðÚòÄÛÆå×)
  • primary transcript
    ÀÏÂ÷ Àü»çü(ìéó­ï®ÞÐô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ETCO2 end-tidal carbon dioxide [concentration]
ETPCO2 end-tidal partial carbon dioxide [concentration]
FECO2 fractional concentration of carbon dioxide in expired gas
FiCO2, FICO2 fractional concentration of carbon dioxide in inspired gas
PACO2 partial pressure of carbon dioxide in alveolar gas
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TiO2 Titanium dioxide
AME Apparent Mineralocorticoid Excess
BE Base Excess
EWL Excess Weight Loss
EPOC Excess post-exercise oxygen consumption
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • carbon paper
    ±³ÇÕÁö
    ÀÚ¿¬ Ä¡¾Æ³ª ¸ðÇü»ó¿¡¼­ »óÇÏ Ä¡¾Æ »çÀÌ¿¡ ³Ö°í ±³ÇÕ½ÃÄÑ Á¢ÃË °ü°è¸¦ °Ë»çÇÏ´Â ¸ÔÁö¿Í °°Àº °Í. µÎ²²°¡ ¾ã°í, ±¤¹üÀ§ÇÏ°Ô ¹¯Áö ¾Ê´Â °ÍÀϼö·Ï ÁÁ´Ù. Á¤È®ÇÑ ±³ÇÕÀÇ ¼ö¸³°ú ±³ÇÕ °£¼·À» Á¶Á¤ÇÏ´Â µ¥ »ç¿ëµÈ´Ù.
  • one carbon moiety
    ÀÏź¼Ò ¸ðÀÌ¾îÆ¼
  • A alpha primary afferent
    A ¾ËÆÄ ÀÏÂ÷ ±¸½É ½Å°æ
    ±Ù¹æÃß ³»ÀÇ ±Ù ¼¶À¯¿¡ Á¸ÀçÇÏ´Â °¨°¢½Å°æÀÇ Çϳª·Î ¥°a °¨°¢ ½Å°æÀ̶ó°íµµ ÇÑ´Ù. Á÷°æÀº 22§­, Àüµµ ¼Óµµ´Â 120§½ÀÌ´Ù.
  • C primary afferent nociceptor
    C ÀÏÂ÷ ±¸½É¼º Ä§ÇØ ¼ö¿ëü, C ÀÏÂ÷ ±¸½É¼º À¯ÇØ ¼ö¿ë±â
  • early primary closure
    Á¶±â 1Â÷ ºÀÇÕ
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • myelinated primary afferent
    ÀÏÂ÷ À¯¼öÃÊ ±¸½É ½Å°æ
  • nociceptive primary afferent
    Ä§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ½Å°æ, À¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ½Å°æ
  • non-nociceptive A delta C primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ, ºñÀ¯ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ
  • non-nociceptive myelinated primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯
  • primary
    ÀÏÂ÷¼º, ¿ø¹ß¼º, ¿ø¹ß¼ºÀÇ, ÀÏÂ÷, ÀÏÂ÷ÀÇ, ÀÏÂ÷¼ºÀÇ, Á¦ÀÏÀÇ, ÃʱâÀÇ, ¿ø¹ßÀÇ, ÁÖµÈ
    ¹ß»ýµÇ´Â ½Ã±âÀÇ ¼ø¼­¿¡ À־ óÀ½ÀÎ.
  • primary adaptation
    ÀÏÂ÷ ¼øÀÀ, ÀÏÂ÷¼º ¼øÀÀ
  • primary adrenocortical insuffciency
    ¿ø¹ß¼º ºÎ½Å ÇÇÁú ±â´É ºÎÀü
  • primary afferent axon
    ÀÏÂ÷ ±¸½É¼º Ãà»è
  • primary afferent cell body
    ÀÏÂ÷ ±¸½É¼º ¼¼Æ÷ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
excess lactate The increase in lactate concentration beyond what would be expected from the increase in pyruvate concentration resulting from a change in redox potential; used as an index of anaerobic carbohydrate metabolism.
(05 Mar 2000)
zinc excess Too much zinc can cause gastrointestinal irritation (upset stomach), interfere with copper absorption and cause copper deficiency, and (like too little zinc) cause immune deficiency. According to the national academy of sciences, the recommended dietary allowances of zinc are 12 milligrams per day for women and 10 milligrams per day for men.
(12 Dec 1998)
colloidal silicon dioxide A submicroscopic fumed silica prepared by the vapor-phase hydrolysis of a silicon compound; used as a tablet diluent and as a suspending and thickening agent.
(05 Mar 2000)
hydrogen dioxide <chemical> Hydrogen peroxide is produced by vertebrate phagocytes and is used in bacterial killing (the myeloperoxidase halide system).
(05 May 1997)
silicon dioxide <chemical> Silica. Transparent, tasteless crystals found in nature as agate, amethyst, chalcedony, cristobalite, flint, sand, quartz, and tridymite. The compound is insoluble in water or acids except hydrofluoric acid.
Chemical name: Silica
(12 Dec 1998)
nitrogen dioxide <chemical> Nitrogen oxide (no2). A highly poisonous gas. Exposure produces inflammation of lungs that may only cause slight pain or pass unnoticed, but resulting oedema several days later may cause death. It is a major atmospheric pollutant that is able to absorb uv light that does not reach the earth's surface.
Pharmacological action: oxidants, photochemical, poisons.
Chemical name: Nitrogen oxide (NO2)
(12 Dec 1998)
sulfur dioxide <chemical> A highly toxic, colourless, nonflammable gas. It is used as a pharmaceutical aid and antioxidant. It is also an environmental air pollutant.
Pharmacological action: air pollutants, environmental, antioxidants, pharmaceutic aid.
Chemical name: Sulfur dioxide
(12 Dec 1998)
dioxide <chemistry> An oxide containing two atoms of oxygen in each molecule; binoxide.
An oxide containing but one atom or equivalent of oxygen to two of a metal; a suboxide. Carbon dioxide. See Carbonic acid, under Carbonic.
Origin: Pref. Di- + oxide.
Source: Websters Dictionary
(01 Mar 1998)
thorium dioxide <chemical> Thorium oxide (tho2). A radiographic contrast agent that was used in the early 1930s through about 1954. High rates of mortality have been linked to its use and it has been shown to cause liver cancer.
Pharmacological action: carcinogens.
Chemical name: Thorium oxide (ThO2)
(12 Dec 1998)
titanium dioxide TiO2;contains not less than 99.0% and not more than 100.5% of TiO2, calculated on the dry basis; used in creams and powders as a protectant against external irritations and solar rays.
(05 Mar 2000)
1,4-diethylene dioxide 1,4-dioxane;a colourless liquid used as a solvent for cellulose esters and in histology as a drying agent.
Synonym: 1,4-diethylene dioxide.
(05 Mar 2000)
anomeric carbon The reducing carbon of a sugar; C-1 of an aldose, C-2 of a 2-ketose.
(05 Mar 2000)
carbon <chemistry, element> Sixth element (Z=6) in the periodic table, has 6 protons, often described as the basis of life on earth because of its chemical properties, has potential for use with silicon as a low-activation structural material for fusion reactors, in the form silicon carbide.
Carbon tiles are often used in plasma-facing components because its low Z makes carbon a relatively nice impurity. It is also useful as a neutron moderator.
See: low-activation materials, plasma-facing components.
Abbreviation: C
(13 Nov 1997)
carbon-11 A cyclotron-produced, positron-emitting radioisotope of carbon with a half-life of 20.3 minutes; used in positron-emitting tomography.
(05 Mar 2000)
carbon-12 The standard of atomic mass, 98.90% of natural carbon.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gas carbon
    °¡½º Ä«º»;°¡½ºÅº(¼®Åº°¡½º Á¦Á¶Áß¿¡ »ý±â´Â)
  • primary
    Áß¿äÇÑ
  • closed primary
    Á¦ÇÑ ¿¹ºñ ¼±°Å(´ç¿ø À¯ÀÚ°ÝÀÚ¸¸ÀÌ ÅõÇ¥ÇÏ´Â Èĺ¸ÀÚ ¼±°Å)
  • dircct primary
    Á÷Á¢ ¿¹¼±
  • indirect primary
    (¹Ì)°£Á¢ ¿¹ºñ ¼±°Å
  • open primary
    °ø°³ ¿¹¼± ´ëȸ
  • presidential primary
    (°¢ Á¤´çÀÇ)´ëÅë·É ¼±°ÅÀÎ ¿¹¼±È¸
  • primary
    ÃÖÃÊÀÇ;¿ø½ÃÀûÀÎ;¼öÀ§ÀÇ;ÁÖ¿äÇÑ;º»·¡ÀÇ;±Ùº»ÀÇ;Ãʺ¸ÀÇ;Á¦ 1±âÀÇ;1Â÷ÀÇ-Á¦ 1À§ÀÇ »ç¹°;¿ø»ö;ÀÏÂ÷¾î(¸í»ç »ó´ç ¾î±¸);´ëÅë·É Èĺ¸ ¿¹ºñ ¼±°Å
  • primary accent
    Á¦ ÀÏÀÇ ¾Ç¼¾Æ®
  • primary assembly
    ¿¹¼± ´ëȸ;»çÀü ÇùÀÇȸ
  • primary atypical pneumonia
    1Â÷¼º ºñÁ¤Çü Æó·Å
  • primary care
    ÀÏÂ÷ ÀÇ·á(ÀÀ±Þ Ä¡·á µî ÁÖ°ÅÁö¿¡¼­ ÇàÇÏ´Â Ãʱâ ÀÇ·á)
  • primary cell
    1Â÷ ÀüÁö
  • primary coil
    1Â÷ ÄÚÀÏ
  • primary colors
    ¿ø»ö(»¡°­,³ë¶û,ÆÄ¶û)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á